Allergy & Immunology
OTHER
EUFOREA summit sets priorities for allergy and respiratory care research and advocacy
Frontiers in Medicine
Published April 1, 2026
DOI ↗
A report from a EUFOREA summit details the establishment of priorities for research, education, and advocacy in the field of allergy and respiratory care. The focus is on conditions including chronic rhinosinusitis, allergic rhinitis, asthma, and allergen immunotherapy, with a mention of pediatric considerations. The document is a position or consensus statement, not a clinical trial or observational study.
No specific study design, patient population, sample size, intervention, comparator, or clinical outcomes are reported. The main results section is empty, and no quantitative data on efficacy or effectiveness are provided. Safety and tolerability information, including adverse events and discontinuations, are also not reported.
Key limitations include the absence of any clinical data, patient demographics, or methodological details. The practice relevance and funding or conflicts of interest are not reported. This document serves solely to outline a strategic agenda for future work in this clinical area, offering no direct evidence to guide current patient management.
When you're dealing with chronic allergies, asthma, or sinus problems, it can feel like you're navigating a confusing system. A group of medical experts just held a summit to try to clear a path forward. They gathered to establish priorities for research, education, and advocacy specifically for people with these chronic inflammatory respiratory conditions. The goal is to build a coordinated plan to improve care. It's important to know this was a planning meeting. No new treatments were tested, and no specific results about what works best were announced. The value here is in the focus—getting experts aligned on what to tackle next for patients who need better answers.
What this means for you: Experts are mapping a better future for allergy and asthma care.
View Original Abstract ↓
EUFOREA, the European Forum for Research and Education in Allergy and Airways diseases, is an international non-for-profit organisation of physicians, patients, and other stakeholders committed to the improvement of outcomes for patients suffering from chronic inflammatory respiratory conditions through collaborative research, education, and targeted advocacy. In February 2025, EUFOREA hosted its biennial summit in Brussels, convening expert panels, its Patient Advisory Board, and a range of leadership representatives. This event was pivotal in establishing the research, educational, and advocacy priorities for the subsequent 2-year period, coinciding with the organisation's 10th anniversary in April 2025. Building on its core competencies, EUFOREA advances evidence-based clinical tools and educational initiatives designed to narrow the gap between emerging science and routine care. In alignment with the objective of enhancing global healthcare standards, the specialists' panels of chronic rhinosinusitis and European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergic rhinitis, asthma, allergen immunotherapy, and paediatrics have devised and detailed a comprehensive range of initiatives that address significant unmet needs within the domains of allergy and respiratory care. This document presents a summary of EUFOREA's future objectives, aspirations, and strategy, providing a clear direction for the coming years. It serves as a valuable resource for individuals and organisations involved in both the allergy and the respiratory sectors, offering a comprehensive overview of the association's plans and initiatives.
